Stereotaxis Receives CE Mark and Submits Synchrony System to FDA
Stereotaxis (NYSE:STXS) announced that it has received CE mark for its Synchrony system and submitted it to the FDA.
The Synchrony system, designed to digitize and modernize the interventional cath lab, features a 55" 4K ultra-high-definition display to consolidate viewing and control of lab systems.
- Enhanced procedure experience with custom layouts and streamlined workflows
- Intuitive user interface and decluttered environment
- Digitized video streams with full fidelity and low latency for clear visualization
- Obsolescence protection for labs with new technologies
Synchrony is available with SynX, a cloud-based app for secure remote connectivity, collaboration, recording, and monitoring of the cath lab.
No additional information is available at this time.
Author summary: Stereotaxis receives CE mark and submits Synchrony system.